Highlights CEL-SCI Corporation

Equities

CVM

US1508376076

Market Closed - Nyse Other stock markets 21:00:00 09/05/2024 BST			5-day change	1st Jan Change
1.51 ^USD	+8.63%		+2.03%	-44.49%

05-08	Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine	MT
05-08	CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine	05-08	CI
CEL-SCI Corporation Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer	05-08	CI
CEL-SCI Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	02-14	CI
CEL-SCI Corporation Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug	02-06	CI
Cel-Sci Receives Pediatric Requirements Waiver for Multikine From European Medicines Agency	01-31	MT
CEL-SCI Corporation Reports Earnings Results for the Full Year Ended September 30, 2023	12-21	CI
CEL-Sci Corporation Releases Video Detailing Recent Phase 3 Findings & Its Plans to Seek Immediate Regulatory Approvals	24/10/23	CI
CEL-SCI Presents the Data for the First Time at the European Society for Medical Oncology Congress in Spain	23/10/23	CI
CEL-SCI Corporation Readies Its Multikine Manufacturing Facility for Commercial Scale Production	19/10/23	CI
Cel-Sci Files Request With UK Regulator for Approval Pathway of Multikine to Treat Head, Neck Cancer	05/10/23	MT
Cel-Sci Files Request with the Uk's Mhra Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer	05/10/23	CI
Cel-Sci Submits Scientific Advice Filing to European Medicines Agency for Multikine in the Treatment of Head & Neck Cancer	26/09/23	CI
CEL-SCI Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	10/08/23	CI
CEL-SCI Corporation Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikineâ€™s Increased Efficacy and Points to Potential for Combination with Checkpoint Inhibitors for Head & Neck Cancer	12/07/23	CI
CEL-SCI Corporation to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer--New Patent to Be Filed	22/06/23	CI
CEL-SCI Corporation Announces Latest Results from Its Pivotal Phase 3 Study of Multikine	15/05/23	CI
CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	12/05/23	CI
CEL-SCI Corporation Reports New Data from Its Pivotal Phase 3 Study	08/03/23	CI
CEL-SCI Corporation Reports Earnings Results for the First Quarter Ended December 31, 2022	14/02/23	CI
CEL-SCI Corporation Reports Earnings Results for the Full Year Ended September 30, 2022	27/12/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CEL-SCI Corporation

Equities

CVM

US1508376076

Highlights

Filters